Blacks with liver cancer more likely to die, study finds

December 20, 2010

ANN ARBOR, Mich. -- Black people with early stage liver cancer were more likely than white patients to die from their disease, according to a new study from the University of Michigan Comprehensive Cancer Center.

Five years after diagnosis, 18 percent of white liver cancer patients were alive but only 15 percent of Hispanic patients and 12 percent of black patients were. Median survival times ranged from 10 months for whites and Hispanics to 8 months for blacks.

The researchers also found racial and ethnic disparities in how often patients received treatment, with black and Hispanic patients less likely than whites to have any kind of treatment.

When researchers looked at survival only among patients who had been treated, the disparity in survival persisted, but the gap narrowed, especially for Hispanics. Blacks who had surgery lived a median 29 months, Hispanics 40 months and whites 43 months. Median survival for all races was only four to six months without treatment.

"Just under a third of the patients we looked at received treatment, which is a significant underuse of appropriate interventions for the most treatable stages of liver cancer," says study author Christopher J. Sonnenday, M.D., M.H.S., assistant professor of surgery at the U-M Medical School and assistant professor of health management and policy at the U-M School of Public Health.

Researchers looked at data from 13,244 patients with early stage hepatocellular carcinoma, or liver cancer. Patients were identified through the Surveillance and Epidemiology End Results registry, a database from the National Cancer Institute that collects information on cancer incidence, prevalence and survival.

Results of the study appear in the December issue of Archives of Surgery.

Liver cancer incidence is increasing, and the disease is difficult to treat in its later stages. Patients diagnosed with advanced disease have only a 5 percent chance of living five years after diagnosis. Early stage disease is more treatable, with options including tumor ablation, surgery to remove a portion of the liver or liver transplant surgery.

"Liver cancer requires highly complex care that is available only in larger referral hospitals. Our study suggests that not only do members of different racial and ethnic groups face barriers to accessing this care, but the survival of blacks and Hispanics even after receiving these treatments appears to be inferior to whites," Sonnenday says.
-end-
Liver cancer statistics: About 24,000 Americans will be diagnosed with liver cancer this year and 18,900 will die from the disease, according to the American Cancer Society

Additional authors: U-M Department of Surgery House Officers Amit K. Mathur, M.D., M.S.; Nicholas H. Osborne, M.D.; Raymond J. Lynch, M.D., M.S.; and Amir A. Ghaferi, M.D.; and Justin Dimick, M.D., M.P.H., assistant professor of surgery

Funding: National Institutes of Health

Disclosure: None

Reference: Archives of Surgery, Vol. 145, No. 12, pp. 1158-1163, Dec. 20, 2010

Resources:
U-M Cancer AnswerLine, 800-865-1125
U-M Comprehensive Cancer Center, www.mcancer.org
Clinical trials at U-M, www.UMClinicalStudies.org

University of Michigan Health System

Related Liver Cancer Articles from Brightsurf:

Eating less suppresses liver cancer due to fatty liver
Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan.

New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

A new treatment for liver cancer
In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.

New study indicates exercise can help prevent liver cancer
Liver cancer is the fourth most common cause of cancer death worldwide and is growing rapidly due to the 'diabesity pandemic.' A new study reported in the Journal of Hepatology, published by Elsevier, provides strong evidence that voluntary exercise could help prevent the most common type of liver cancer, hepatocellular carcinoma, and identifies the molecular signaling pathways involved.

From obesity to liver cancer: Can we prevent the worst?
Hepatocellular carcinoma, a liver cancer linked to the presence of fat in the liver, is one of the leading causes of cancer death worldwide.

Liver cancer deaths climb by around 50% in the last decade
Liver cancer deaths have increased by around 50% in the last decade and have tripled since records began, according to the latest calculations by Cancer Research UK.

NUS researchers show potential liver cancer treatment by targeting cancer stem-like cells
NUS researchers from the Cancer Science Institute of Singapore and the N.1 Institute for Health have shown the potential use of small molecule inhibitors to treat advanced liver cancer.

Breast cancer gene a potential target for childhood liver cancer treatment
Hepatoblastoma is a rare liver cancer that mainly affects infants and young children and is associated with mutations in the β-catenin gene.

Blood transfusion during liver cancer surgery linked with higher risk of cancer recurrence and death
Receiving a blood transfusion during curative surgery for the most common type of liver cancer (hepatocellular carcinoma) is associated with a much higher risk of cancer recurrence and dying prematurely, according to new research being presented at this year's Euroanaesthesia congress.

Read More: Liver Cancer News and Liver Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.